A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

NCT04504916 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

102

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Triple-negative Breast Cancer
Non-squamous Non-small-cell Lung Cancer
NSCLC
Estrogen-receptor-positive Breast Cancer
Progesterone-receptor-positive Breast Cancer
Estrogen-receptor-negative Breast Cancer
ER-negative Breast Cancer
Progesterone-receptor Negative Breast Cancer
PR-negative Breast Cancer
HER2-negative Breast Cancer
ER-positive Breast Cancer
PR-positive Breast Cancer
Platinum-resistant Ovarian Cancer
Gastric Cancer
Pancreatic Cancer

Interventions

DRUG: Zilovertamab vedotin

Sponsor

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)